Evidence map›Paper›PMID 40643915›Full record

Trial reportJAMA network open2025

Intensive Systolic Blood Pressure Reduction and Kidney and Cardiovascular Outcomes: A Secondary Analysis of a Randomized Clinical Trial.

Guozhe Sun, Wei Miao, Songyue Liu, Yangzhi Yin, Danxi Geng, Ning Ye, Ziyi Xie, Linlin Zhang, Shiyu Zhou, Chang Wang and 6 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03527719 (Effectiveness of a Standardized Protocol-based Treatment Program on Hypertension Control in Rural China), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03527719 naactive not recruitingnot on this map

Effectiveness of a Standardized Protocol-based Treatment Program on Hypertension Control in Rural China

TypeinterventionalSponsorFirst Hospital of China Medical UniversityRan2018 to 2026Enrolled33,995ConditionsHypertensionArmsVillage-doctor-led multifaceted intervention
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Guozhe SunDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Wei MiaoDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Songyue LiuDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Yangzhi YinDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Danxi GengDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Ning YeDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Ziyi XieDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Linlin ZhangDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Shiyu ZhouDepartment of Clinical Epidemiology and Evidence-Based Medicine, The First Hospital of China Medical University, Shenyang, China.
Chang WangDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Lixia QiaoDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Sitong PeiDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Nanxiang OuyangDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Chuning ShiDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Xiaofan GuoDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Yingxian SunDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Intensive blood pressure (BP) control is effective in reducing major cardiovascular events. However, whether the reduction of systolic BP may lead to kidney injury remains controversial. Objective: To elucidate the association of intensive BP control with kidney and cardiovascular outcomes in individuals with hypertension without chronic kidney disease. Design, Setting, and Participants: This study is a secondary analysis of the China Rural Hypertension Control Project (CRHCP), an open-label, blind-end-point cluster randomized trial conducted from May 8, 2018, to March 15, 2023, in 326 villages in China. Patients with a baseline estimated glomerular filtration rate (eGFR) of 60 mL/min/1.73 m2 or greater were randomized to an intervention or usual care group, stratified according to eGFR level. Exposures: A nonphysician community health care professional implemented a multifaceted intervention program after training to achieve a BP treatment goal of less than 130/80 mm Hg. Main Outcomes and Measures: Kidney outcome was defined as an eGFR decrease of 30% to a rate less than 60 mL/min/1.73 m2. Composite cardiovascular outcomes included cardiovascular death, stroke, myocardial infarction, and heart failure. Results: A total of 33 332 patients with a baseline eGFR of 60 mL/min/1.73 m2 or greater were included in this subgroup analysis (mean [SD] age, 62.8 [9.1] years; 61.3% female). After 36 months of follow-up, in 7562 participants with eGFRs between 60 and 90 mL/min/1.73 m2, 121 participants in the intervention group and 101 in the usual care group (risk ratio, 1.17; 95% CI, 0.82-1.62; P = .36) experienced kidney outcome, which was not statistically significant. As for cardiovascular outcomes, 210 participants (2.0% per year) in the intervention group and 346 participants (3.3% per year) in the usual care group had the composite cardiovascular disease outcome, and the disparity between the 2 groups was statistically significant (hazard ratio, 0.57; 95% CI, 0.47-0.68; P < .001). Conclusions and Relevance: This secondary analysis of the CRHCP study suggests that intensive BP control was associated with reduced incidence of the composite cardiovascular disease outcome but not increased risk of kidney injury in patients without chronic kidney disease. These findings provide further evidence supporting the implementation of intensive BP control in patients without chronic kidney disease. Trial Registration: ClinicalTrials.gov Identifier: NCT03527719.

Indexed as

Antihypertensive AgentsCardiovascular DiseasesHypertensionAgedBlood PressureChinaFemaleGlomerular Filtration RateHumansMaleMiddle AgedSecondary Data AnalysisAntihypertensive Agents

Identifiers

PMID40643915
PMCPMC12254891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.